×

Food and Staples Retailing Drug Retail

  • JOHANNESBURG, Nov 18- South Africa's Dis-Chem plans to double in size over the next five years its chief executive said on Friday, as the drug store chain made its debut on the Johannesburg bourse. The company braved uncertain equity markets in South Africa's second largest listing this year after food services group Bidcorp, which made its debut in May at a...

  • JOHANNESBURG, Nov 18- South African drug store chain Dis-Chem made its debut on the Johannesburg bourse on Friday, giving its founders a chance to partially cash in on their investment and bring a rival to the main pharmacy merchant on the bourse. Founded by Chief Executive Ivan Saltzman and his wife Lynette, Dis-Chem has grown from a start-up in 1978 to a major...

  • JOHANNESBURG, Nov 18- South African drug store chain Dis-Chem made its debut on the Johannesburg bourse on Friday, with its shares opening at 23.26 rand and valuing it at around 20 billion rand. Founded by chief executive Ivan Saltzman and his wife Lynette, Dis-Chem is tapping an uncertain equity market as it looks to take on larger rival Clicks Group and...

  • The new war on drugs

    Ravi Mehrotra, MTS Partners, and CNBC's Meg Tirrell discuss the high cost of pharmaceuticals in America and what can be done to rein prices in.

  • Nov 16- Canadian grocery and pharmacy retailer Loblaw Cos Ltd reported a 25.5 percent rise in quarterly profit, helped by a drop in expenses and improved performances by its financial services and property businesses. Adjusted net earnings attributable to shareholders rose to C $512 million, or C $1.26 per share, in the third quarter ended Oct. 8, from C $408...

  • Drug pricing pressure

    CNBC's Meg Tirrell speaks with Alkermes Chairman & CEO Richard Pops at the Partnering for Cures conference about drug pricing, his company's new depression drug and the opioid epidemic.

  • A study comparing three popular arthritis drugs shows they're all about equally safe and equally dangerous for the heart, reports NBC.

  • Nov 8- CVS Health Corp, the No. 2 U.S. drugstore chain by store count, reported a 15.5 percent rise in quarterly revenue, helped by strong demand for its pharmacy benefit management services. Net income attributable to CVS rose to $1.54 billion, or $1.43 per share, in the third quarter ended Sept. 30, from $1.25 billion, or $1.11 per share, a year earlier.

  • Cali's drug price brawl

    CNBC's Meg Tirrell reports the latest surrounding California's Proposition 61.

  • New war on drugs: Pharma becoming 'uninvestable'?

    Bill George, Harvard Business School Professor and former Medtronic Chairman and CEO, and David Maris, Wells Fargo Securities Specialty Pharmaceutical Analyst, weigh in on the ongoing drug-pricing war.

  • Big pharma's big problem

    CNBC's Meg Tirrell discusses the timeline on the war on drug pricing.

  • Nov 3- CVS Health Corp said it would cut about 600 jobs, mostly at its corporate offices in Rhode Island, Illinois and Arizona over the next two months, citing an increasingly competitive environment. The drugstore chain operator, which is expected to report third-quarter results next week, employs more than 240,000 people in the United States.

  • Generic drug probe charges to be filed by year end -Rpt

    CNBC's Dominic Chu reports on possible charges being filed by the Justice Department against some generic drugmakers, according to Bloomberg.

  • Gilead Q3 EPS misses, revenues beat

    Earnings are out for Gilead. CNBC's Meg Tirrell reports the details. “Fast Money” trader Jon Najarian weighs in.

  • Drug Price Relief Act battle

    Debating whether California voters should pass Proposition 61, the Drug Price Relief Act, with Scott Gottlieb, physician and American Enterprise Institute Resident Fellow, and Zeke Emanuel, University of Pennsylvania vice provost for global initiatives.

  • Cramer: The drug wholesale price war has officially begun — steer clear

    Jim Cramer addressed the stunning decline in McKesson, and got to the bottom of what triggered the sudden fall in the stock.

  • Washington's next biotech target?

    CNBC's Meg Tirrell reports the latest surrounding Ariad Pharmaceuticals and the company's drug price hike.

  • Ariad cancer drug pricing under congressional scrutiny

    CNBC's Meg Tirrell reports the latest on a tweet sent by Sen. Bernie Sanders about Ariad Pharmaceuticals' cancer drug pricing.

  • *Reports 4th- qtr adj. profit of $1.07/ shr vs est. Forecasts FY adj. profit of $4.85- $5.20/ shr, includes Rite Aid. The No. 1 U.S. drugstore operator by store count said it expected to divest the 500-1,000 stores it needs to shed to win approval for the $9.4 billion acquisition by the end of 2016, and now expects the deal to close on Jan. 27.

  • A Walgreens store in Boston.

    Walgreens Boots Alliance reported a jump in quarterly profit and said it now expected its acquisition of Rite Aid Corp to close in early 2017.